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S U M M A R Y
Background: A high seroprevalence of Toxoplasma gondii infection has been detected in psychiatric
patients, particularly in schizophrenia cases.
Methods: In the present study 98 patients suffering from schizophrenia (58 inpatients and 40 ﬁrst-
episode patients) and 96 control patients (50 healthy volunteers and 46with a depressive disorder) were
examined for the presence of both IgG and IgM antibodies against T. gondii by enzyme-linked
immunosorbent assay (ELISA). We applied the Bradford Hill criteria to identify the weight of causal
inference.
Results: The positivity rate of anti-T. gondii IgG antibodies among individuals with schizophrenia (57.1%)
was signiﬁcantly higher than in healthy controls (29.2%). There were no associations between immune
status ratio (ISR) values and the risk of schizophrenia. The weight of evidence approach using the
Bradford Hill criteria revealed a 92% probability of a causal association.
Conclusion: Our results show that exposure to T. gondii may lead to schizophrenia.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Schizophrenia is a complex neuropsychiatric disorder and a
challenging mental illness, with an uncertain etiology. This
disorder is characterized by delusions, hallucinations, disturbances
in thinking and communication, and withdrawal from social
activity, and affects approximately 1% of the adult population in
the USA and Europe.1
Epidemiological data indicate that some infections including
herpes simplex, rubella, polio, and varicella zoster virus may
contribute to schizophrenia.2–4 Recent studies have also corrobo-
rated the hypothesis that T. gondii, an important zoonotic and
persistent infection in humans and livestock, is a prime candidate
in this contribution, and it is now considered a possible cause of
schizophrenia. Studies have shown that patients with schizophre-
nia have signiﬁcantly increased levels of antibodies to T. gondii
compared with healthy controls.1,5
T. gondii is an obligate intracellular protozoan parasite that is a
member of the phylum Apicomplexa, order Coccidia,6,7 and felids
are the most important deﬁnitive and reservoir hosts for this
parasite.8 Humans become infectedwith T. gondii in three principal
ways: congenitally, through the ingestion of raw or undercooked* Corresponding author.
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poorly washed raw fruits and vegetables contaminated with
sporulated oocysts from the feces of infected cats.9 Research has
revealed that individuals with schizophrenia have had a greater
exposure to cats in childhood than adulthood.8
Inmost adults,T. gondiidoesnot cause serious illness, andclinical
manifestations are often not apparent.10 Blindness and mental
retardation in children can result froma congenital infection and the
disease can be severe in those with depressed immunity. Also,
reactivation and replication of T. gondii in immunocompromised
individuals can lead to neurological or psychiatric symptoms.
Whereas epidemiological and neuropathological studies have
shown that some cases of schizophrenia may be associated with
toxoplasmosis,1 the main aim of this study was to compare the
prevalence of T. gondii infection between individuals with
schizophrenia and depressive disorders (as a statistically con-
founding factor) and healthy controls, and to compare the immune
status ratio (ISR) in individuals in the examined groups to
investigate any association between T. gondii infection and
schizophrenia based on psychiatric status.
2. Materials and methods
This cross-sectional study was undertaken in four populations:
inpatients and ﬁrst-episode individuals with schizophrenia,
individuals with depressive disorders, and healthy volunteers.ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Analysis of anti-Toxoplasma gondii IgG and IgM antibodies in schizophrenia patients
and in the control groups
First episode Depressed Inpatient Healthy
(n=40) (n=46) (n=58) (n=48)
IgG-positive 24 (60%) 15 (32.6%) 32 (55.2%) 14 (29.2%)
IgM-positive 2 (5%) 2 (4.3%) 2 (3.4%) 2 (4.2%)
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Clinical Interview for the Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV).11
Of the schizophrenia patients, 40 were ﬁrst-episode individuals
and 58 were inpatients; they were not immunodeﬁcient and did
not have any other abnormalities or neurological disease. The
control groups consisted of 46 patients with depressive disorders
and 48 healthy volunteers.
Themedian age of the patients and controls was 33 years (range
18–58 years). After receiving permission from the patient and their
family (at the neuropsychiatry hospital), blood sampleswere taken
under sterile conditions by means of venipuncture. Samples were
uniformly handled, centrifuged at 1000  g, and the sera were
stored at 20 8C until serological examination.
Commercially available enzyme-linked immunosorbent assay
(ELISA) kits (Trinity Biotech, USA) were used according to the
manufacturer’s instructions, and a microtiter plate reader (405–
690 nm; Dynatech, Iceland) was used to determine the IgG and IgM
antibodies in serum samples. The ISR of each sample was
determined by dividing the optical density of the sample by the
cut-off value (cut-off = mean optical density of the calibra-
tors correction factor). As per the manufacturer’s recommenda-
tion, serawithan ISR0.90were regardedasnegative, thosewithan
ISR between 0.90 and 1.10 were regarded as suspicious, and those
with an ISR 1.10were considered positive. International standard
unit values were calculated by the formula presented below.
ex ¼ derived IU=ml; e ¼ Neperiannumber;X ¼ ðY þ bÞ=a; a
¼ 0:864;b ¼ 1:566;Y ¼ ISR
International standard units were evaluated statistically for all
groups to compare the intensity of seropositivity and seronegativ-
ity in specimens from schizophrenic patients and controls.
Statistical analyses were carried out using SPSS software
version 16 (SPSS Inc., Chicago, IL, USA). The Chi-square test was
performed to compare IgG levels in all groups, as well as Fisher’s
exact test for IgM levels. Odds ratios (OR) with 95% conﬁdence
intervals (95% CI) were also determined to estimate the strength of
association. International standard units were compared by one-
way analysis of variance (one-way ANOVA). We also applied the
Bradford Hill criteria to identify the weight of causal inference.12
3. Results
Individuals with schizophrenia had signiﬁcantly increased
levels of serum IgG antibodies to T. gondii (57.1%) as comparedTable 2
Weight of evidence approach using the Bradford Hill criteria for the association betwe
Hill’s criterion Evidence
Constant
Strength Strong OR detected
Consistency Many studies have revealed the association
Speciﬁcity Other neurological disorders reported
Temporality Maternal exposure to toxoplasmosis and exposure to cat in ch
the risk factors for schizophrenia in adults
Dose–response Epidemiologically there are many similarities between toxopla
and schizophrenia
Plausibility Mice and rats with T. gondii have cognitive dysfunction and
behavioral changes
Coherence T. gondii affects neurons and glial cells
Experimental
evidence
Anti-schizophrenia drugs can inhibit growth of T. gondii
Analogy Some infective agents may contribute to schizophrenia
Sum
Final probability e11.118418/(e11.118418 + e8.67599) =92%to controls (29.2%) (p < 0.05). The OR for this association was 2.99
with 95% CI = 1.655.41.
Of the 192 individuals examined, anti-T. gondii IgG antibodies
were present in 60% (24 of 40) of those with ﬁrst-episode
schizophrenia, 55.2% (32 of 58) of inpatient cases with schizo-
phrenia, 32.6% (15 of 46) of thosewith a depressive disorder, and in
29.2% (14 of 48) of healthy volunteers (Table 1).
Theweight of evidence approach using the BradfordHill criteria
revealed a 92% probability of a causal association (Table 2).
The prevalence of anti-T. gondii IgG antibodies in the ﬁrst-
episode schizophrenia group was not signiﬁcantly different to that
of the inpatient group (p > 0.05).With regard to the control groups,
there was also no statistically signiﬁcant difference between the
IgG levels of those with a depressive disorder and healthy controls
(p > 0.05). However, there was a signiﬁcant increase in IgG levels
in both ﬁrst-episode and inpatient schizophrenia individuals
compared with depressed and healthy controls, respectively
(p < 0.05).
IgM antibodies were detected in 4.1% of cases with schizophre-
nia (5% in the ﬁrst-episode group and 3.4% in the inpatient group)
and 4.3% of controls (4.3% in depressed and 4.2% in healthy
controls). There were no statistically signiﬁcant differences
between IgM levels in the examined groups (p > 0.05).
No association was found between international standard unit
values of IgG or IgM antibodies to T. gondii for all seropositive and
seronegative sera in all groups and the risk of schizophrenia
(Figures 1 and 2).
4. Discussion
Our ﬁndings replicate the results of recent studies that have
shown higher anti-T. gondii IgG antibodies in individuals with
schizophrenia than in controls.1,5
Using the Bradford Hill criteria we established that the
association between toxoplasmosis and schizophrenia is causative.
We also found that both ﬁrst-episode (those who have not had a
previous hospitalization) and inpatient schizophrenia patients haden toxoplasmosis and schizophrenia
Probability
(%)
Probabilityweight
for category 1
Probabilityweight
for category 2A
14.7799 10.08346
80 4.9784 1.5384
95 3.85795 1.71285
60 1.6722 2.3262
ildhood are 100 7.657 8.281
smosis 60 2.1168 2.1204
60 13.815 13.0134
80 0.076968 0.2672
40 0.3372 0.2672
80 1.0352 0.8088
11.118418 8.67599
[(Figure_2)TD$FIG]
Figure 2.Mean and standard deviation of international standard units (units/ml) for
anti-Toxoplasma gondii IgM antibodies in all examined groups.
[(Figure_1)TD$FIG]
Figure 1.Mean and standard deviation of international standard units (units/ml) for
anti-Toxoplasma gondii IgG antibodies in all examined groups.
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with depressed and healthy controls, respectively, but we did not
ﬁnd any statistical difference in the levels of IgG antibodies
between ﬁrst-episode and inpatient schizophrenia cases. It is
possible that the sample size in this study was not sufﬁcient to
obtain signiﬁcant results or that hospitalization of the patients did
not have any effect on the contamination of inpatients with T.
gondii. Also, we found no signiﬁcant difference between indivi-
duals with depressive disorders as a confounding factor and the
healthy control group in the relationship between T. gondii
infection and schizophrenia.
As shown in other studies,13,14 IgM antibodies were not
signiﬁcantly different between the groups. This is due to the fact
that IgM is an indicator of recent infection and becomes negative
within 4–12 weeks,15 so presumably is not associated with the
increased risk of schizophrenia.
As yet, the mechanism of T. gondii infection on the manifesta-
tion of schizophrenia is not clear. T. gondii infects the central
nervous system (CNS) and forms latent tissue cysts in neurons and
other permanent cells.16 Research has found that mice and rats
infected with T. gondii experience cognitive dysfunction and
behavioral changes and that infected humans show changes in
psychomotor skills and personality,17–20 or suffer psychotic
symptoms such as delusions and hallucinations.21 This parasite
also manipulates the behavior of the intermediate host and causes
neurological and psychiatric symptoms in some infected indivi-
duals.22Different in neuropathological effects, T. gondii and schizophre-
nia affect neurons and glial cells. Schwarcz and Hunter speculated
that prominent activation of resident glial cells, in particular
astrocytes, by T. gondii infection in the CNS may play a role in the
development of schizophrenia.23 Astrocytes are the main cells
responsible for the synthesis of kynurenic acid (KYNA), which
inhibits N-methyl-D-aspartate (NMDA) and a7 nicotinic acetyl-
choline (a7nACh) receptors when present at slightly elevated
concentration levels. These receptors are linked to cognitive
processes. KYNA levels are also increased in the brains of
schizophrenia patients.24,25
On the other hand, postmortem studies of brains from
individuals who had schizophrenia have revealed glial abnormali-
ties.26 However, Conejero-Goldberg et al. did not detect T. gondii
sequences in the postmortem brains by nested-polymerase chain
reaction.27
Evidence points to the fact that T. gondii affects function and the
levels of neurotransmitters including dopamine; likewise, indivi-
duals with schizophrenia have abnormal dopamine levels. Flegr et
al. believe that the activation of interleukin-2 following infection
by T. gondii may result in the subsequent increase in dopamine
levels, and that dopamine is the missing link between schizophre-
nia and T. gondii infection.3
All these ﬁndings indicate that T. gondiimay play an important
role in the pathogenesis of schizophrenia.
5. Conclusions
We still do not know exactly what causes schizophrenia.
Moreover, genetic and environmental factors contribute to
susceptibility to this disorder. Many studies have demonstrated
that the risk of schizophrenia runs in families.1 People in urban
areas have an increased risk of being diagnosedwith schizophrenia
in later life compared to those in rural areas.1 It appears that a
combination of genetic and acquired factors may be involved in
schizophrenia.
Our study supports the role of T. gondii in the etiology of
schizophrenia and found no difference between ﬁrst-episode and
inpatient individuals with schizophrenia. This shows that chronic
toxoplasmosis has notable and plausible epidemiologic and
symptomatic similarities to schizophrenia. Furthermore, effective
anti-schizophrenia and bipolar disorder drugs are able to inhibit
the growth of T. gondii.28 However, in spite of the correlations
hypothesized bymany authors, further comprehensive studies and
a greater accumulation of evidence are required to determine the
precise association between these two disorders.
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